Juzar Ali, MD
Pulmonary Disease · New Orleans, LANPI 1508887522
Payments from drug & device makers
Across 541 payments — averaging $1431.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$680K
- Oxford Immunotec USA Inc$50K
- Paratek Pharmaceuticals, Inc.$33K
- Zambon USA Ltd.$5K
- Revvity, Inc.$3K
- Redhill Biopharma Inc.$2K
- plus $499 from 8 others
What the payments were for
- Consulting fees$111,89752%
- Speaking & faculty fees$67,87531%
- Travel & lodging$30,18814%
- Food & beverage$5,7583%
- Education$1320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 476 | $680,278 |
| Oxford Immunotec USA Inc | 26 | $50,186 |
| Paratek Pharmaceuticals, Inc. | 8 | $33,398 |
| Zambon USA Ltd. | 6 | $4,891 |
| Revvity, Inc. | 1 | $3,000 |
| Redhill Biopharma Inc. | 1 | $2,350 |
| Electromed, Inc. | 15 | $183 |
| AstraZeneca | 2 | $132 |
| Abbott | 1 | $90 |
| Baxter Healthcare | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$131,486
- TSPOT TB TEST$49,937
- Brinsupri$1,323
How this compares
$774,602 in reported general payments places this provider in the 95th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $594 |
| Azithromycin | 11 | $190 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Ramsy AbdelghaniNew Orleans$474K
- Bennett DeboisblancNew Orleans$457K
- Nereida ParadaNew Orleans$289K
- Nicole LapinelNew Orleans$225K
- Joshua DensonNew Orleans$222K
- Amita KrishnanNew Orleans$205K
- Courtney ShappleyNew Orleans$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.